Akos Heinemann - Curriculum Vitae#

• Since 2021 Director of Otto Loewi Research Center, Medical University of Graz, Austria
  
• Since 2010 Head of Division of Pharmacology, Medical University of Graz, Austria
  
• 2009 Full Professor of Pharmacology, Medical University of Graz
  
• 2003 Board Certified Specialist in Pharmacology, Austrian Med. Association
  
• 2000 Habilitation in Pharmacology and Associate Professorship, Institute of Pharmacology, Karl Franzens University of Graz Medical School, Graz, Austria
  
• 1998 - 1999 Post-doctoral Research Fellow, Imperial College School of Medicine, London, UK (Prof. T.J. Williams)
  
• 1993 - 1998 Research Fellow, Institute of Pharmacology, Karl Franzens University of Graz Medical School, Graz, Austria
  
• 1992 - 1995 Fellow in Internal Medicine (Graz), Surgery (Kalwang) and Dermatology/Allergology (Graz), Austria
  
• 1991 M.D. degree
  
• 1984 - 1991 Medical student, Karl Franzens University of Graz Medical School, Graz, Austria

• Since 2013 Member and since 2023 Chairman of the Academic Senate of the MUG
  
• Since 2004 Board member of the Ethics Committee of the MUG
  
• 2006 - 2024 Coordinator of the “PhD Program Molecular Medicine” at the MUG
  
• Since 2006 Advisory board member for Astra Zeneca, Amgen and Bayer
  
• 2010 - 2021 Speaker of the FWF-funded “Doctoral College MOLIN” at the MUG
  
• 2014 – 2023 Board member of the Austrian Science Fund FWF
  
• Since 2022 Member of the Drug Evaluation Committee of the Austrian Federal Social Insurance Services
  
• Since 2022 President of the Austrian Pharmacological Society

• Number of published full articles: 211, cumulative impact factor: 1196, total citations: 8786, H-index: 55
  
• Invited referee for >40 scientific journals and >10 funding organizations
  
• Main supervisor of 16 PhD thesis (plus 4 ongoing)

• 2021 - 2025 FWF, DOC129, Role of succinate and GPR91 in lung fibrosis, € 220,000
  
• 2018 - 2022 FWF, DOC31, Role of prostaglandin receptors in the placenta, € 220,000
  
• 2017 - 2020 Austrian Academy of Science (ÖAW) DOC, Role of 15-prostaglandin dehydrogenase in idiopathic pulmonary fibrosis, € 110,000
  
• 2014 - 2018 FWF, P26185, Imatinib as a novel prostaglandin-releasing drug (with R. Schuligoi), € 330,000
  
• 2013 - 2018 FWF, P25531-B23, Role of PGE2 and EP receptors in the pulmonary endothelial function (with V. Konya), € 327,000
• 2015 - 2018, Austrian Academy of Science (ÖAW) DOC, Short chain fatty acids as regulators of eosinophil function, € 110,000
  
• 2012 - 2021 FWF and MUG (DK-MOLIN), W1241, Leukocyte trafficking and inflammatory mediators, € 820,000
  
• 2010 - 2015 FWF, P22521, Prostaglandin receptors in the treatment of allergy, € 310,000
  
• 2012 - 2015 OeNB, 14263, Effect of the novel lipid-lowering therapy niacin plus laropiprant on platelet function, € 89,000